Research progress of MSI-CRC on anti-PD-1 therapy
10.3760/cma.j.issn115396-20201209-00391
- VernacularTitle:MSI-CRC抗PD-1免疫治疗的研究进展
- Author:
Yuzhe LI
1
;
Liang YU
;
Jikun LI
Author Information
1. 上海交通大学医学院附属上海市第一人民医院普外科
- Keywords:
Colorectal neoplasms;
Microsatellite instability;
Immunity;
Mismatch repair deficient;
Programmed cell death receptor 1
- From:
International Journal of Surgery
2021;48(8):565-571
- CountryChina
- Language:Chinese
-
Abstract:
The programmed cell death receptor 1 (PD-1) antibody has been used in the treatment of a variety of malignant tumors, in which colorectal cancer is considered immune " cold" tumor and is not sensitive to anti-PD-1 therapy. The molecular characteristics of mismatch repair deficient (dMMR)/high microsatellite instability (MSI-H) are important molecular markers for screening patients with immune checkpoint inhibitors therapy (ICIs). However, only some patients can benefit from ICIs treatment, and some patients even have disease progression. This article summarizes the research progress of anti-PD-1 immunotherapy of MSI-CRC in recent years, including the mechanisms of resistance, new efficacy biomarkers and treatment options, so as to provide ideas for expanding the application of immunotherapy in colorectal cancer.
